Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?

Viking Therapeutics (VKTX) shares fell 39.2% on August 20 after its oral anti-obesity candidate, VK2735, demonstrated poor tolerability in Phase 2 clinical trials, with 35% of patients experiencing vomiting at higher doses, undermining its commercial viability against established competitors despite weight loss efficacy. While this setback for the oral formulation is significant, Viking's pipeline includes an injectable version of VK2735 currently in Phase 3, along with other clinical-stage assets for MASH and rare diseases, suggesting its post-drop market valuation of approximately $2.9 billion may not fully account for its remaining development potential.

Analysis

Viking Therapeutics (VKTX) experienced a significant 39.2% stock price decline following the release of Phase 2 trial data for its oral anti-obesity candidate, VK2735. The primary driver of this sell-off was a poor safety and tolerability profile, where 35% of patients on the higher, more effective doses reported vomiting. This rate is substantially higher than the 13% reported for Eli Lilly's approved injectable, Zepbound, raising serious concerns about the oral drug's commercial viability in a market where long-term patient adherence is critical. Despite this major setback for the oral formulation, the company's investment thesis now hinges on its remaining pipeline. The injectable version of VK2735, which demonstrated up to 14.7% weight loss in its Phase 2 trial, is advancing into a large-scale Phase 3 study with results expected in approximately two years. Furthermore, Viking possesses other clinical-stage assets, including VK2809 for MASH, which has completed a successful Phase 2 study, and VK0214 for a rare disease. The market has repriced the company to a market capitalization of around $2.9 billion, a valuation that appears to heavily discount the potential success of the injectable VK2735 and its other pipeline candidates.

Key Decisions for Investors

• Investors should evaluate Viking Therapeutics as a high-risk, speculative investment, where the recent share price collapse may present a value opportunity if the injectable VK2735 proves successful in its pivotal Phase 3 trial.
• The primary catalyst to monitor is the clinical progress and eventual data readout from the Phase 3 Vanquish trial for the injectable VK2735, expected in approximately two years, as this is now the key determinant of the company's future value.
• Consider that the failure of the oral candidate significantly de-risks the competitive landscape for established players like Eli Lilly and Novo Nordisk, and any potential approval for Viking's injectable will still face a high commercial barrier.
• Given the binary risk associated with clinical-stage biotechnology firms, any position in VKTX should be sized appropriately for a portfolio with a high tolerance for potential volatility and capital loss.